ES2037243T3 - Tiazolidindionas como agentes hipoglicemicos y anti-ateroscleroticos. - Google Patents

Tiazolidindionas como agentes hipoglicemicos y anti-ateroscleroticos.

Info

Publication number
ES2037243T3
ES2037243T3 ES198888311018T ES88311018T ES2037243T3 ES 2037243 T3 ES2037243 T3 ES 2037243T3 ES 198888311018 T ES198888311018 T ES 198888311018T ES 88311018 T ES88311018 T ES 88311018T ES 2037243 T3 ES2037243 T3 ES 2037243T3
Authority
ES
Spain
Prior art keywords
agents
thiazolidindionas
aterosclerotic
hypoglycemic
hypoglucemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198888311018T
Other languages
English (en)
Inventor
David Alan Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2037243T3 publication Critical patent/ES2037243T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Seasonings (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA(UI) EN LA QUE LA LINEA DISCONTINUA ES UN ENL/ACE OPCIONAL Y SUS SALES CATIONICAS FARMACEUTICAMENTE ACEPTABLES, QUE TIENEN UTILIDAD COMO AGENTES HIPOGLUCEMICOS Y ANTIATEROESCLEROTICOS, Y A COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
ES198888311018T 1987-12-02 1988-11-22 Tiazolidindionas como agentes hipoglicemicos y anti-ateroscleroticos. Expired - Lifetime ES2037243T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/127,831 US4791125A (en) 1987-12-02 1987-12-02 Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents

Publications (1)

Publication Number Publication Date
ES2037243T3 true ES2037243T3 (es) 1993-06-16

Family

ID=22432189

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198888311018T Expired - Lifetime ES2037243T3 (es) 1987-12-02 1988-11-22 Tiazolidindionas como agentes hipoglicemicos y anti-ateroscleroticos.

Country Status (11)

Country Link
US (1) US4791125A (es)
EP (1) EP0319189B1 (es)
JP (1) JPH01186884A (es)
AT (1) ATE77087T1 (es)
DE (1) DE3871916T2 (es)
DK (1) DK671088A (es)
ES (1) ES2037243T3 (es)
FI (1) FI89356C (es)
GR (1) GR3004902T3 (es)
IE (1) IE883599L (es)
PT (1) PT89122B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU203330B (en) * 1987-06-10 1991-07-29 Pfizer Process for producing oxazolidin-2-one derivatives and hypoglychemic pharmaceutical compositions containing them
US5053420A (en) * 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
ES2092539T3 (es) * 1991-01-10 1996-12-01 Transcend Therapeutics Inc Uso de derivados de la tiazolidina-4-carboxilato para el tratamiento de enfermedades pulmonares.
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
US5866595A (en) * 1991-09-26 1999-02-02 The Regents Of The University Of California Calcium antagonists for treatment of vascular restenosis
US5430045A (en) * 1992-04-23 1995-07-04 Free Radical Sciences, Inc. Method of reducing or preventing bone marrow hypoplasia
US5498621A (en) * 1992-05-01 1996-03-12 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5306724A (en) * 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
US5447712A (en) * 1993-12-09 1995-09-05 Free Radical Sciences Method of reducing cyclophosphamide induced hemorrhagic cystitis
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
PL198018B1 (pl) 1997-06-18 2008-05-30 Smithkline Beecham Plc Kompozycja farmaceutyczna przeciwcukrzycowa zawierająca sulfonylomocznik i tiazolidynodion i jej zastosowanie
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
CZ20011629A3 (cs) 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
AR023700A1 (es) 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
RU2273642C2 (ru) * 1999-12-22 2006-04-10 Метабэйсис Терапьютикс, Инк. Бисамидатные фосфонатные соединения, являющиеся ингибиторами фруктозо-1,6-бисфосфатазы
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20080200453A1 (en) * 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
WO2006023515A2 (en) * 2004-08-18 2006-03-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
EP2217073B1 (en) 2007-06-21 2019-10-09 VeroScience LLC Method of treating metabolic disorders and depression with dopamine receptor agonists
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
WO2016071727A1 (en) 2014-11-04 2016-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
US4617312A (en) * 1983-01-17 1986-10-14 Pfizer Inc. Aldose reductase inhibiting 5-(2-alkoxyphenyl) thiazolidinediones
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
HU210339B (en) * 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
JPH1036284A (ja) * 1996-07-24 1998-02-10 Sumitomo Pharmaceut Co Ltd プロテアソーム阻害剤

Also Published As

Publication number Publication date
FI885594A (fi) 1989-06-03
DK671088D0 (da) 1988-12-01
DE3871916D1 (de) 1992-07-16
EP0319189A1 (en) 1989-06-07
JPH0465075B2 (es) 1992-10-16
DK671088A (da) 1989-07-20
DE3871916T2 (de) 1992-12-03
EP0319189B1 (en) 1992-06-10
FI89356B (fi) 1993-06-15
PT89122A (pt) 1989-12-29
PT89122B (pt) 1993-05-31
JPH01186884A (ja) 1989-07-26
IE883599L (en) 1989-06-02
ATE77087T1 (de) 1992-06-15
FI89356C (fi) 1993-09-27
GR3004902T3 (es) 1993-04-28
FI885594A0 (fi) 1988-12-01
US4791125A (en) 1988-12-13

Similar Documents

Publication Publication Date Title
ES2037243T3 (es) Tiazolidindionas como agentes hipoglicemicos y anti-ateroscleroticos.
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
ES2053778T3 (es) Procedimiento para la obtencion de derivados del tiazol.
ES2175161T3 (es) Derivados de piperazina como antagonistas de taquiquinina.
BR9806296A (pt) Derivados de ácido sulfìnico e sua preparação e uso
ES2064700T3 (es) Derivados de adenosina con actividad farmaceutica como antihipertensivos.
AR038434A2 (es) Compuesto 14,15-dihidro-16-oxoparahercuamida y compuestos 2-desoxo de parahercuamida y marcfortina
ECSP034460A (es) Nuevos compuestos heterociclicos, su preparacion y su utilizacion como medicamentos, en especial como antibacterianos
ES2114931T3 (es) Nuevos esteres esteroidales.
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
ES2045180T3 (es) Nuevo procedimiento para la obtencion de 4-aciloxi-3-hidroxietil-azetidinonas.
ES2083348T1 (es) Derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il)-metoxi-1,3-propandiol.
ES2002254T3 (es) Nuevos 5-alcoxi-2,4-diamino-alquilbenzenos asi como tintes para el cabello con 5-alcoxi-2,4-diamino-alquil-benzenos.
MX9307644A (es) Medicamento que incluye 2-amino-6-n-propil-amino-4,5, 6, 7,-tetrahidrobenzotiazol con efecto antidepresivo.
ES2029842T3 (es) Procedimiento para preparar un derivado de quinolina.
ES2043863T3 (es) Procedimiento para preparar derivados de la 1,2,5,6-tetrahidropiridina.
ES2053511T3 (es) Derivados de acidos aminocarboxilicos biciclicos, procedimiento y productos intermedios para su preparacion, asi como su empleo.
MX9305773A (es) 5-oxo-dibenzo/a,d/ciclohepta-1,4-dienos, procedimiento para su obtencion y medicamentos que los contienen.
ES2125354T3 (es) Composicion a base de tandospirona o de sus analogos.
ES2100263T3 (es) Nuevas isohirudinas sinteticas con estabilidad mejorada.
AR008494A1 (es) Empleo de las pirazolinonas para el tratamiento de los trastornos de la potencia, preparaciones farmaceuticas que las contienen, empleo de estaspreparaciones farmaceuticas para el tratamiento y/o la terapia de los trastornos de la potencia y un procedimiento para prepararlas
ES2062997T3 (es) Vinilcefalosporinas sustituidas, procedimiento para su fabricacion y su uso como medicamento.
GT199900084A (es) Derivados de 3-(2-oxo-[1,3']bipirrolidinil-3-ilidenemetilo)-cefems.
ES2036533T3 (es) Derivados de 1,6-naftiridina, procedimientos para su obtencion y de medicamentos que los contienen para el tratamiento de enfermedades de los vasos sanguineos.
AR003093A1 (es) Nuevos derivados de imidazol-n-bencildioxol, su procedimiento de preparacion, su aplicacion a titulo de medicamentos, composicionesfarmaceuticas y nueva utilizacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 319189

Country of ref document: ES